Related Experiment Video
Updated: Aug 18, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
[Cardiac dysfunction induced by trastuzumab]
Mario Campone1, Emmanuelle Bourbouloux, Pierre Fumoleau
1Centre René-Gauducheau, Boulevard Jacques-Monod, 44805 Nantes Cedex. m-campone@nantes.fnclcc.fr
Abstract:
Trastuzumab combined to chemotherapy had demonstrated significant improvement of time to progression and survival in metastatic breast cancer patient overexpressing HER-2. Cardiac toxicity was an unexpected side effect. The incidence of cardiac dysfunction was dependent on prior or current anthracycline exposure. The mechanism of action involved for this cardiac toxicity is unclear. We discuss in this article the incidence, the physiopathology, the risk factors, the predictive factors and the patient management and on cardiotoxicity of trastuzumab.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Cardiomyopathy IV: Restrictive Cardiomyopathy